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In Saccharomyces cerevisiae, lysine 4 on histone H3 (H3K4) is
methylated by the Set1 complex (Set1C or COMPASS). Besides
the catalytic Set1 subunit, several proteins that form the Set1C
(Swd1, Swd2, Swd3, Spp1, Bre2, and Sdc1) are also needed to
mediate proper H3K4 methylation. Until this study, it has been
unclear how individual Set1C members interact and how this
interaction may impact histone methylation and gene expres-
sion. In this study, Bre2 and Sdc1 are shown to directly interact,
and it is shown that the association of this heteromeric complex
is needed for proper H3K4 methylation and gene expression to
occur. Interestingly, mutational and biochemical analysis iden-
tified the C terminus of Bre2 as a critical protein-protein inter-
action domain that binds to the Dpy-30 domain of Sdc1. Using
the human homologs of Bre2 and Sdc1, ASH2L and DPY-30,
respectively, we demonstrate that the C terminus of ASH2L also
interacts with the Dpy-30 domain of DPY-30, suggesting that
this protein-protein interaction is maintained from yeast to
humans. Because of the functionally conserved nature of the C
terminus of Bre2 and ASH2L, this region was named the SDI
(Sdc1 Dpy-30 interaction) domain. Finally, we show that the
SDI-Dpy-30 domain interaction is physiologically important for
the function of Set1 in vivo, because specific disruption of this
interaction prevents Bre2 and Sdc1 association with Set1,
resulting in H3K4 methylation defects and decreases in gene
expression.Overall, these and othermechanistic studies on how
H3K4 methyltransferase complexes function will likely provide
insights intohowhumanMLLandSET1-like complexes or over-
expression of ASH2L leads to oncogenesis.
In Saccharomyces cerevisiae, histone H3 lysine 4 (H3K4)3
mono-, di-, and trimethylation is mediated by the Set1 histone
methyltransferase (1, 2). Set1 and H3K4 methylation were first
identified to be required for silencing at rDNA, telomeres, and
mating-type loci (3–6). Set1 and H3K4 trimethylation are also
found to be located at euchromatin and enriched in the 5-ends
of coding regions of transcriptionally active genes (7, 8). In
addition, Set1 and its human homologs, MLL1, MLL2, and
hSET1, associate with the phosphorylated C-terminal domain
of RNA polymerase II (7, 9–11). More recently, it has been
shown that various chromodomain and PHD zinc finger-con-
taining proteins can bind to histones and H3K4 di- and tri-
methylated histone peptides and histones (12–14). Therefore,
these and other studies suggest that Set1-mediated histone
methylation plays a positive role in mediating gene expression
through recruitment of effector proteins.
Unlike other yeast histone methyltransferases, Set1 requires a
multiprotein complex for its activity in vitro and in vivo (1, 15–18).
The yeast Set1 complex, also called Set1C or COMPASS
(complex associated with Set1), consists of eight subunits
(Set1, Bre2, Sdc1, Swd1, Swd2, Swd3, Spp1, and Shg1) (15, 18,
19). After the discovery of yeast Set1C, it was determined that
the human H3K4 methyltransferases MLL1 through 4 and
human SET1 (SET1A and SET1B) form yeast Set1-like com-
plexes (2, 9, 20–26). The human MLL and SET1 complexes
share most of their core subunits, and these are homologous to
the subunits found in the yeast Set1 complex. The core subunits
consist of ASH2/ASH2L (Bre2), DPY30 (Sdc1), RBBP5 (Swd1),
WDR82 (Swd2), WDR5 (Swd3), and CFP1/CGBP (Spp1) (9,
24–27). To date,WDR82 has only been identified in the human
SET1 complexes and not in the MLL complexes (2, 11, 23, 24,
28). In yeast, deletion of the individual Set1-associated genes
BRE2, SDC1, SWD1, SWD3, and SPP1 disrupts, to varying
degrees, the levels ofH3K4mono-, di-, or trimethylation in cells
(15–17, 29). In addition, disruption of the human MLL and
SET1 complex members WDR5, RBBP5, and ASH2L leads to
decreases in H3K4 trimethylation, whereas embryonic stem
cells lacking CFP1/CGBP exhibit an increase in H3K4 trimeth-
ylation (20, 21, 30, 31). These results suggest that the conserved
Set1C subunits in addition to the SET domain catalytic subunit
are essential for maintaining proper H3K4 methylation.
Several of the yeast and human complexmembers have been
shown to interact with each other. In yeast lacking Set1, the
only two heteromeric Set1C subunit interactions that remain
intact are a Swd1-Swd3 heteromer and a Bre2-Sdc1 heteromer
(18, 32). Bre2 and Sdc1 have also been shown to interact via
bacterial two-hybrid analysis, and a Bre2-Sdc1 heteromeric
association is needed for them to interact with Set1 (18, 32).
Interestingly, deletion of either of the Set1C heteromer sub-
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units displays similar defects in H3K4methylation (15–17, 29).
Deletion of SWD1 or SWD3 leads to global loss ofH3K4mono-,
di-, and trimethylation similar to a SET1deletion,whereas dele-
tion of BRE2 or SDC1 results in global loss of H3K4 trimethyl-
ation and reductions in mono- and dimethylation (15–17, 29).
However, how individual yeast or human Set1 complex mem-
bers interact with each other mechanistically and how their
interaction may impact histone methylation and gene expres-
sion has not been thoroughly investigated.
In this study, we focus on defining the interaction of Bre2 and
Sdc1 and how this interaction impacts histonemethylation and
gene expression. We demonstrate that Bre2 and Sdc1 can
directly interact with each other without additional yeast pro-
teins. In addition, we identify that the C termini of Bre2 and
ASH2L are required to bind to the Dpy-30 domain of Sdc1 and
DPY-30, respectively. Because this domain appears to be func-
tionally conserved from yeast to humans, we named this new
domain the SDI (Sdc1 Dpy-30 interaction) domain. More
importantly, disrupting the interaction between the SDI and
Dpy-30 domains prevents Bre2 and Sdc1 association with Set1
and results in defective histone H3K4 methylation and gene
expression. These results show the fundamental importance of
this new and conserved protein-protein interaction domain.
EXPERIMENTAL PROCEDURES
Plasmids and Strains—All yeast strains and plasmids used in
this study are described in the supplemental material (see sup-
plemental Tables S1 and S2). Bacterial and yeast plasmids for
full-length BRE2 and SDC1weremade by PCR amplification of
yeast genomic DNA. PCR-amplified BRE2 was subcloned into
a modified pET28b vector (pET28b-9) and a pGEX-KG vector
to generate pPFS25 and pPFS52. SDC1 was subcloned into a
pGEX-2T and pET28b-9 vector to generate pPFS15 and
pPFS40, respectively. Constructs of BRE2 and SDC1 for in vivo
methylation studies were engineered with a 5-hemagglutinin
(HA) sequence and subcloned into the yeast expression vector
pRS415 containing an ADH1 promoter (pRS415/ADH1p) to
make pPFS1 and pPFS2, respectively. Bre2 and Sdc1 constructs
for co-immunoprecipitation studies were engineered with an
N-terminal HA tag or FLAG tag by PCR and subcloned into a
yeast expression vector under the control of the ADH1 promoter
with a URA3- or LEU2-selectable marker to make pPFS45,
pPFS46, orpPFS43.Plasmidconstructs, pPFS44andpPFS47,were
generated by site-directed mutagenesis using pPFS43 as a tem-
plate.ASH2Lwas subcloned into the pET28b-9 vector to generate
pPFS36, and DPY-30 was subcloned into the pGEX2T vector to
generate pPFS40. Full-length human ASH2L and DPY-30 were
PCR-amplified from a human cDNA library. All bre2, ash2l, sdc1,
and dpy-30 deletions and point mutations were generated either
by PCRamplification or by using the StratageneQuikChange site-
directed mutagenesis method using BRE2-, ASH2L-, SDC1-, and
DPY-30-containing plasmids as templates.
In Vitro Binding Analysis—GST, GST-Sdc1, His6-Bre2, and
His6-Sdc1 constructs were bacterially expressed as described
previously (33, 34). GST pull-down assays were done as
described previously (33, 34). Briefly, GST andGST fusion pro-
teins were bound to glutathione-agarose beads and washed
with Buffer A (300 mM NaCl, 50 mM Tris-HCl pH 8.0, 1 mM
phenylmethylsufonyl fluoride, and 1 g/ml leupeptin, aproti-
nin, and pepstatin A). After washing, 4 g of immobilized GST
fusion proteins were incubated with 400 l of bacterial whole
cell extract containing His6-tagged proteins. GST fusion pro-
tein binding reactions were performed in Buffer A and incu-
bated for 1 h at 4 °Cwith rotation. After 1 h, the beadswere then
washed three times in 1 ml of Buffer A and then resuspended
and boiled in 10 l of 5 SDS sample buffer with 10% -mer-
captoethanol. All 10 l of each sample was loaded per lane on a
12% SDS-polyacrylamide gel, transferred to PVDF membrane,
and immunoblotted using an -His antibody (catalog number
sc-8036, Santa Cruz Biotechnology, Inc. (Santa Cruz, CA)).
After immunoblot analysis, the PVDF membrane was stained
with Coomassie Blue stain to visualize GST and GST fusion
proteins. GST pull-down assays using recombinant GST-
DPY-30 and His6-ASH2L were performed as described above
with the followingmodification. 2g of GST-DPY-30 bound to
glutathione-agarose beads and 150 l of bacteria whole cell
extract containing His6-ASH2L or ASH2L mutants were used
in the binding reaction.
Sdc1 Dimerization and Binding Assays—Bacteria whole cell
extract containing His6-Sdc1 or His6-Sdc1 C47A was prepared
as described above. His6-Sdc1 or His6-Sdc1 C47A was purified
using nickel-agarose beads (Ni2-NTA-agarose, Qiagen) from
whole cell extracts according to the manufacturer’s protocol.
2 SDS sample buffer with or without -mercaptoethanol was
added to Ni2-NTA-agarose beads containing His6-Sdc1 or
His6-Sdc1 C47A. The eluted purified samples were analyzed by
SDS-PAGE and transferred to a PVDFmembrane for immuno-
blot analysis using -His antibody (catalog number sc-8036,
Santa Cruz Biotechnology, Inc.) or stained with Coomassie
Blue. Nickel-agarose binding assays were performed similarly
to theGST fusion binding assays. His6-Sdc1 orHis6-Sdc1C47A
was immobilized on Ni2-NTA beads (Qiagen) and washed
with buffer A (300 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1 mM
phenylmethylsufonyl fluoride, and 1 g/ml leupeptin, aproti-
nin, and pepstatin A). Bacteria whole cell extract containing
GST-Bre2 was incubated with the Ni2-NTA beads for 1 h at
4 °Cwith rotation. After three washes in buffer A, pelleted sam-
ples were boiled in 10 l of 5 SDS sample buffer with 10%
-mercaptoethanol and run on 12% SDS-polyacrylamide gels.
For detection of His6- and GST-tagged Sdc1 and Bre2, SDS-
polyacrylamide gels were transferred to PVDF and immuno-
blotted with -His antibody (catalog number sc-8036, Santa
Cruz Biotechnology, Inc.) or -GST antibody (catalog number
sc-138, Santa Cruz Biotechnology, Inc.).
Yeast Extraction and Immunoblot Analysis—Yeast extrac-
tion and immunoblot analysis to detect modified histones were
performed as previously described (5). -H3K4me1 (catalog
number 07-436), -H3K4me2 (catalog number 07-030), and
-H3K4me3 (catalog number 07-473) were obtained fromMil-
lipore and were used at 1:2500, 1:5000, and 1:5000 dilutions,
respectively. The H3 (catalog number Ab1791, Abcam)-spe-
cific antibody at a 1:5000 dilution was used as a loading control.
HA.11 (catalog numberMMS-101R, Covance) and 12CA5 (cat-
alog number 1666606, Roche Applied Science) antibodies were
used at a 1:5000 dilution to detect HA-tagged Bre2 and Sdc1,
respectively.
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Co-immunoprecipitation Analysis—For co-immunoprecipi-
tation of HA-Bre2 and FLAG-Sdc1, 50-ml yeast cultures were
grown in select media to mid-log phase. Yeast whole cell
extracts were prepared by bead beating in 400 l of lysis buffer
(40 mM HEPES-NaOH, pH 7.5; 350 mM NaCl; 0.1% Tween 20;
10% glycerol; 1 g of leupeptin, aprotinin, and pepstatin A; 1
mM phenylmethylsulfonyl fluoride), and protein levels were
normalized using a Bradford assay as described previously (35).
To each sample, 10 l of M2 -FLAG resin (catalog number
A2220; Sigma) was added to normalized extracts and incubated
for 3 h at 4 °C with rotation. The immunoprecipitated samples
were washed three times in 1 ml of lysis buffer. The remaining
beads from the final wash were resuspended in 2 SDS sample
bufferwith10%-mercaptoethanol andboiled.Each immunopre-
cipitated samplewas split inhalf, and5l of samplewas loadedper
laneona12%SDS-polyacrylamide gel, transferred toPVDFmem-
brane, and immunoblotted using -HA polyclonal antibody (cat-
alog number sc-805, Santa Cruz Biotechnology, Inc.) or -FLAG
polyclonal antibody (catalog number F7425, Sigma). Yeast cell
extracts for loading inputswere detected using-HA (HA.11, cat-
alognumberMMS-101R,Covance) and-FLAG(catalognumber
F7425; Sigma) antibodies.
For immunoprecipitation of Myc3-Set1, the above proce-
dure was performed with the following modifications. To
each sample, 2 g of -Myc antibody (9E10, catalog number
11667203001, Roche Applied Science) was added to normal-
ized extracts and incubated at 4 °C for 2 h. After 2 h, 12 l of
Protein G-Sepharose (catalog number 17-0618-01, GE Health-
care) was added to each sample and incubated for 1 h at 4 °C.
The immunoprecipitated samples were washed three times
with 1 ml of lysis buffer, and the remaining beads were resus-
pended in 10 l of 2 SDS sample buffer with 10% -mercap-
toethanol and boiled. Samples were analyzed on an 8% SDS-
polyacrylamide gel, transferred to a PVDF membrane, and
immunoblotted with -Myc antibody (9E10, catalog number
11 667 203 001, Roche Applied Science). For co-immunopre-
cipitation of HA-Bre2 and FLAG-Sdc1 by Myc3-Set1, Myc3-
Set1 was immunoprecipitated, as described, and analyzed on a
12% SDS-polyacrylamide gel, transferred to PVDF membrane,
and immunoblotted using -HA polyclonal antibody (catalog
number sc-805, Santa Cruz Biotechnology, Inc.) or -FLAG
polyclonal antibody (catalog number F7425, Sigma).
Gene Expression Analysis—Quantitative real-time PCRs
were performed as previously described (35). Briefly, 6-ml cul-
tures of yeast cells were grown to mid-log phase in selective
media. Total RNAwas extracted using the RNeasy kit (Qiagen)
following the manufacturer’s protocol, and 1 g of RNA was
reverse transcribed into cDNA using the Quantitec reverse
transcription kit (Qiagen) according to themanufacturer’s pro-
tocol. The real-time PCR mix consisted of 6.25 l of SYBR
green master mix (Applied Biosystems), 0.125 l of each for-
ward and reverse primer from a 5M stock, 0.5l of cDNA, and
5.5 l of sterile water. DNA was amplified in a StepOne real-
time PCR system (Applied Biosystems) with the following pro-
gram: an initial hold of 95 °C for 10min followed by 40 cycles at
95 °C for 15 s and 60 °C for 1min. Three biological repeats, each
including three technical repeats, were performed for all sam-
ples. Data were analyzed using theCtmethod in which actin
(ACT1) was used as the endogenous control, and relative quan-
tity of MDH2 and GUA1 transcript was determined for each
deletion strain comparedwithMDH2 andGUA1 transcript in a
wild-type strain. Primer sequences used for PCR amplification
are described in supplemental Table S3.
Chromatin Immunoprecipitation Analysis—Chromatin im-
munoprecipitation (ChIP) was performed as previously
described (33, 35). Briefly, 100-ml cultures were grown to mid-
log phase in selective media overnight and split in half. Cells
were harvested and cross-linked with 1% formaldehyde. ChIP
was performed using eitherH3K4 di- or trimethyl-specific anti-
bodies (catalog numbers 07-030 and 07-473, Millipore) or an
antibody specific to H3 (catalog number Ab1791, Abcam) and
Protein G-Sepharose (GE Healthcare). Immunoprecipitated
DNA was amplified by standard PCR methods using primer
sets to analyze the 5- and 3-regions of the MDH2 and GUA1
open reading frames. Amplified PCR products were analyzed
by agarose gel and ethidium bromide staining. Primers used in
ChIP analysis are described in supplemental Table S4.
RESULTS
The Dpy-30 Domain of Sdc1 Is Required for Interaction with
Bre2—In yeast lacking Set1, the Set1 complex is no longer
intact, and only two heteromeric subunit associations remain.
These include an association between Bre2 and Sdc1 and an
association between Swd1 and Swd3 (18). More recently, Bre2
and Sdc1 have also been suggested to interact by bacterial two-
hybrid analysis (32). Together, these studies indicate that the
Bre2 and Sdc1 subunits directly interact. Until now, how Bre2
and Sdc1 or Swd1 and Swd3 interact has not been established.
In this study, we focus on Bre2 and Sdc1 interaction and the
functional significance of this interaction on histone methyl-
ation and gene expression.
To investigate if Bre2 and Sdc1 directly interact, in vitroGST
fusion binding assays were performed in which Escherichia coli
extracts expressing recombinant His6-Bre2 were incubated
with purified GST-Sdc1 fusion protein, GST, or glutathione-
agarose beads. We observed that GST-Sdc1 could pull down
His6-Bre2, indicating direct interaction (Fig. 1B, lane 3). This
binding was specific to a Bre2 and Sdc1 protein-protein inter-
action because Bre2 was not detected when incubated with glu-
tathione-agarose- or GST-containing beads (Fig. 1B, lanes 1
and 2). To determine the region of interaction,mutational anal-
ysis and GST fusion binding assays were used to determine
which regions in Sdc1 were important for interacting with Bre2
(Fig. 1A). We initially hypothesized that the SPRY domain of
Bre2 would be important for this interaction. The SPRY
domain was first identified in the tyrosine kinase spore lysis A
(SplA) and in the mammalian ryanodine receptor (RyR) from
which it was named (36). Because SPRY domain-containing
proteins have recently been shown to interact with proteins
containing asparagine-rich sequences, we looked at the pri-
mary sequence of Sdc1 for asparagine residues (37, 38). Upon
sequence analysis of Sdc1, we identified an N-terminal aspar-
agine-rich region from amino acids 51–60 containing six
asparagines. In addition, the Dpy-30 domain of Sdc1, which is a
domain that was initially found inDPY-30 proteins required for
sex determination and dosage compensation inCaenorhabditis
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elegans, has also been predicted to be a protein-protein inter-
action domain (39, 40). Dpy-30 domains are similar to RIIa
domains found in cAMP protein kinase A regulatory subunits
that are known to dimerize (41–43). Therefore, the Dpy-30
domain of Sdc1 could be facilitating dimerization or interac-
tions with Bre2. To determine if the Sdc1 asparagine-rich
sequence or the Dpy-30 domain was responsible for binding to
Bre2, GST-Sdc1 deletion constructs were generated lacking
these regions (Sdc1 51–60 and Sdc1 1–120) (Fig. 1A). To our
surprise, GST-Sdc1 51–60 lacking the asparagine-rich se-
quence was still able to bind Bre2, similar to when full-length
Sdc1 is used (Fig. 1B, compare lanes 3 and 4). However, GST-
Sdc1 1–120 lacking the Dpy-30 domain was unable to bind to
Bre2, suggesting that the Dpy-30 domain is required for Bre2
interaction (Fig. 1B, lane 5).
Modeling of the yeast Dpy-30 domain suggests that it forms a
structure with an -helix followed by a turn and then another
-helix (44). Interestingly, GST fusion binding assays using
Sdc1 deletions (Sdc1 131–140 and Sdc1 156–165) showed
that disrupting either predicted -helix abolishes binding to
Bre2 (Fig. 1, A and B, lanes 9 and 10). Because the deletions
within the predicted -helices of the Dpy-30 domain abolished
binding to Bre2, we wanted to mutate conserved residues
located in one of the predicted -helices. Based on sequence
alignment between various organisms, we identified two highly
conserved leucine residues, Leu-134 and Leu-135 (Fig. 1A and
supplemental Fig. S1A). These resi-
dues are located in the first pre-
dicted -helix of the Dpy-30 do-
main of Sdc1. Interestingly, based
on the x-ray crystal structure of the
human Dpy-30 domain of DPY-30,
it has been suggested that these
two conserved leucine residues are
probably forming a putative binding
pocket (45). Similar to deletions
within the predicted -helix, all
Sdc1 Leu-134 and Leu-135 muta-
tions (Sdc1 L134E,L135E, Sdc1
L134A,L135A, and Sdc1 L134I,
L135I) disrupted binding to Bre2,
suggesting that the Dpy-30 domain
of Sdc1 might be sufficient to medi-
ate binding to Bre2 (Fig. 1B, lanes
16–18). In addition, another highly
conserved region found in the
Dpy-30 domain of Sdc1 is a PXXP
motif, which is likely to form a turn
and link the two predicted -heli-
ces. Similar to deleting the con-
served leucine residues, a PXXP
deletion (Sdc1 146–149) is also
unable to bind to Bre2 (Fig. 1, A and
B, lane 11). Furthermore, Sdc1
point mutations (Sdc1 P146A and
P149A) converting the PXXP motif
to an AXXA motif also completely
disrupt binding of Bre2 to Sdc1,
indicating that the PXXPmotif is another important conserved
region of the Dpy-30 domain (Fig. 1,A and B, lane 12). Because
mutations in conserved amino acids in the predicted turn
region and -helix region of the Dpy-30 domain of Sdc1 dis-
rupted binding to Bre2, we wanted to determine if the Dpy-30
domain in itself was sufficient in binding to Bre2 in vitro. Two
sizes for the yeast Dpy-30 domain have been reported based on
sequence alignments with conserved residues, with one being
41 amino acids in size by Pfam and the other 50 amino acids
long published by Dong et al. (46) (supplemental Fig. S1A).
Therefore, a GST-Sdc1 fusion construct representing the
Dpy-30 domain of Sdc1 and the remaining C terminus of Sdc1
(Sdc1 121–175) was generated and used in a GST binding assay
(Fig. 1A). Our results indicated that the Dpy-30 domain of Sdc1
is sufficient to bind full-length Bre2 (Fig. 1B, lane 22).
Previous bacterial two-hybrid results suggest that Sdc1
might dimerize (32). In addition, the DPY-30 crystal structure
was solved as a dimer, and RIIa domains have also been shown
to dimerize; therefore, we sought to determine if bacterially
expressed Sdc1 can dimerize in vitro (41, 43, 45). Interestingly,
Sdc1 dimers were detected on non-reducing polyacrylamide
gels and disrupted in the presence of the sulfhydryl-reducing
agent -mercaptoethanol, suggesting that a cysteine residue is
mediating this event (Fig. 2,A andB). Because only one cysteine
is present in Sdc1, we mutated it to an alanine (Sdc1 C47A); as
expected, this pointmutation disrupted dimerizationwhen run
FIGURE 1. The Dpy-30 domain of Sdc1 is required for interaction with Bre2 in vitro. A, schematic represen-
tation of Sdc1 and Sdc1 mutants used. The position of the Dpy-30 domain is indicated. B, GST fusion binding
assays were performed to determine the region within Sdc1 responsible for binding Bre2. Purified GST-Sdc1 or
GST-Sdc1 mutants were used to pull down bacterially expressed His6-Bre2 from whole cell extracts. GST and
glutathione-agarose beads (Agarose) were used as controls for nonspecific binding. Input and bound fractions
of His6-Bre2 were detected by immunoblotting using an -His monoclonal antibody. Immunoblots were
stained with Coomassie Blue to indicate the amount of GST, GST-Sdc1, and GST-Sdc1 mutant proteins used.
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on non-reducing gels (Fig. 2, A and B). To determine if Sdc1
disulfide-mediated dimerization was important for binding to
Bre2, a GST-Bre2 fusion protein was incubated with a His6-
Sdc1 C47A point mutation (Fig. 2C). In addition, GST-Sdc1
and GST-Sdc1 C47A were incubated with His6-Bre2 (Fig. 2D).
In both cases, the Sdc1 C47A point mutation, which failed to
dimerize in vitro, was still capable of binding Bre2, suggesting
that disulfide-mediated dimerization does not facilitate inter-
action between Sdc1 and Bre2 (Fig. 2, C and D). We were also
unable to detect Sdc1 cysteine-mediated dimers when isolated
from yeast (data not shown), suggesting that cysteine-mediated
dimerization of Sdc1 is probably an artifact of bacterial expres-
sion. Altogether, our results show that Bre2 and Sdc1 can
directly interact in vitro and indicate that theDpy-30 domain of
Sdc1 is functionally necessary and sufficient for interaction
with Bre2.
The C Terminus of Bre2 Is Required for Binding Sdc1—Be-
causewe determined that theDpy-30 domainwas necessary for
Sdc1 interaction with Bre2, we wanted to determine the region
of Bre2 important for interacting with Sdc1. The only known
putative protein-protein interaction domain found within Bre2
is the SPRY domain (15, 18). Therefore, we predicted that the
conserved SPRY domain of Bre2would be the site of Sdc1 bind-
ing. Utilizing the GST fusion binding assay, GST-Sdc1, GST,
and glutathione-agarose beads were incubated with extracts
expressing either full-length His6-Bre2 or various His6-Bre2
truncation and deletion mutants
(Fig. 3A). Again, GST-Sdc1 was able
to associate with full-length Bre2
but not with GST or glutathione-
agarose (Fig. 3B, panel 1). However,
a Bre2 C-terminal truncation
mutant (Bre2 1–124) lacking the
SPRY domain and the C terminus
was unable to bind to Sdc1 (Fig. 3B,
panel 2). In addition, a Bre2 trunca-
tionmutant (Bre2 114–505) lacking
theN terminus of Bre2 but retaining
the SPRY domain andC terminus of
Bre2 was able to bind to Sdc1 (Fig.
3B, panel 3). These results suggest
the possibility that the SPRY do-
main or the C terminus of Bre2 is
the domain necessary for binding
Sdc1.
To determine if the SPRY domain
of Bre2 was responsible for binding
to Sdc1, a Bre2 deletion mutant
(Bre2 130–393) lacking the SPRY
domain and a Bre2 truncation
mutant (Bre2 114–404) lacking the
N and C terminus but containing
the SPRY domain and 10 residues of
surrounding flanking sequences
were generated and tested for inter-
action with Sdc1 (Fig. 3A). Surpris-
ingly, Sdc1 could still bind the Bre2
deletion mutant lacking the SPRY
domain (Bre2 130–393) but was not able to bind the Bre2 N-
and C-terminal truncation mutant containing an intact SPRY
domain (Bre2 114–404) (Fig. 3B, compare panels 4 and 5).
These results clearly indicated that that the SPRY domain is not
necessary for interaction with Sdc1 and suggest that an
unknown domain in the C terminus of Bre2 is needed for the
Bre2 and Sdc1 interaction.
To confirm that theC terminus of Bre2 is the region towhich
Sdc1 binds, a Bre2 truncation mutant lacking the C terminus
(Bre2 1–404) and a Bre2 mutant lacking the N terminus (Bre2
394–505) were generated and tested for binding to Sdc1 (Fig.
3A). Again, a Bre2 truncation mutant lacking its C terminus
(Bre2 1–404) was unable to bind Sdc1, whereas the Bre2
mutant lacking the N terminus (Bre2 394–505) could still bind
Sdc1 (Fig. 3B, panels 6 and 7). This suggests that the C terminus
of Bre2 is important for Sdc1 interaction. To further define the
C-terminal region in Bre2 responsible for binding Sdc1, three
Bre2 deletion constructs (Bre2 410–421, Bre2 445–474,
and Bre2 475–500) were generated (Fig. 3A). Although the
Bre2 deletion mutant (Bre2 410–421) could bind to Sdc1,
similar to wild-type Bre2, Bre2 445–474 had a significant
defect in its ability to bind Sdc1 (Fig. 3B, panels 8 and 9). How-
ever, Sdc1 binding was completely abolished when using the
Bre2 475–500 deletion mutant, indicating that these amino
acids of Bre2 are key determinants for interacting with Sdc1
(Fig. 3B, panel 10).
FIGURE 2. Sdc1 forms a dimer by a disulfide interaction. A, immunoblot analysis of purified His6-Sdc1 and
His6-Sdc1 C47A in the presence and absence of the reducing agent -mercaptoethanol (-ME). B, Coomassie
Blue stain of purified His6-Sdc1 and His6-Sdc1 C47A in the presence and absence of the reducing agent -mer-
captoethanol. Bands representing Sdc1 monomer and dimer are labeled accordingly. C, nickel-agarose bind-
ing assays were performed to determine if Sdc1 dimerization affected interaction with Bre2. Purified His6-Sdc1
and His6-Sdc1 C47A were used to pull down bacterially expressed GST-Bre2 from whole cell extracts. Ni
2-NTA-
agarose beads were used as a control for nonspecific binding. Input and bound fraction of GST-Bre2, His6-Sdc1,
and His6-Sdc1 C47A were detected by immunoblotting with -GST or -His monoclonal antibodies. D, GST
fusion binding assays were performed to determine if the GST-Sdc1 C47A mutation affected binding of His6-
Bre2. Purified GST-Sdc1 or GST-Sdc1 C47A was used to pull down bacterially expressed His6-Bre2 from whole
cell extracts. Glutathione-agarose- or GST-bound beads were used as a control for nonspecific binding. Input
and bound fractions of His6-Bre2, GST, GST-Sdc1, and GST-Sdc1 C47A were detected by immunoblotting with
-His monoclonal antibodies and Coomassie Blue staining of the immunoblot.
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Because the Bre2 445–474 deletion mutant almost abol-
ishes binding to Sdc1, we wanted to further define the region of
Bre2 needed for binding Sdc1. Therefore, two smaller Bre2
C-terminal deletionswere generated (Bre2445–464 and Bre2
464–474) and tested for their ability to bind Sdc1 (Fig. 4A).
Interestingly, both Bre2 deletions (Bre2 445–464 and Bre2
464–474) were capable of binding to Sdc1 similar to full-
length Bre2 (Fig. 4B, compare panels 1–3). Therefore, the Bre2
445–474 deletion mutant that nearly abolishes interaction
with Sdc1 is likely due to the size of the deletion and is probably
disrupting the ability of the C-terminal residues 475–505 of
Bre2 to interact with Sdc1.
Our data show that C-terminal residues 475–500 of Bre2 are
necessary for interaction with Sdc1 (Fig. 3B, panel 10). How-
ever, to determine if this region is sufficient for interacting with
Sdc1, two Bre2 truncation mutants (Bre2 445–505 and Bre2
475–505) were generated and tested for binding to Sdc1 (Fig.
4A). Our results show that Bre2 445–505 andBre2 475–505 can
bind Sdc1 similar to full-length Bre2 (Fig. 4C, compare lanes
3–5). Therefore, the C-terminal region of Bre2 encompassing
amino acid residues 475–505 is not only necessary but also
sufficient for interaction with the Dpy-30 domain of Sdc1. In
summary, our in vitro results demonstrate that the C terminus
of Bre2 and the Dpy-30 domain of Sdc1 are both necessary and
sufficient for binding to Sdc1 and Bre2, respectively. Further-
more, we have defined a novel protein-protein interaction
domain in Bre2 that probably consists of amino acids 475–505,
which we have designated the SDI domain.
Previous work has suggested that
the Set1 complex may contain two
copies of Bre2 by a Bre2 dimer (1,
32). To test if Bre2 does interact
with itself, we performed an in vitro
pull-down assaywithGST-Bre2 and
His6-Bre2. Our data show that we
can pull down Bre2 with Sdc1, but
we are unable to detect a direct
interaction of Bre2 with itself, sug-
gesting that Bre2 does not dimerize
(Fig. 4D, compare lanes 3 and 4).
This result indicates that if there are
multiple Bre2 subunits in the Set1
complex, they may not be interact-
ing directly with each other as a
dimer. However, additional quanti-
tative experiments will be needed to
determine the accurate stoichiom-
etry of Bre2 within the Set1 complex.
Interaction between Human
ASH2L and DPY-30 Occurs through
the C Terminus of ASH2L and the
Dpy-30 Domain of DPY-30—Con-
sistent with the previous findings
for the Bre2 and Sdc1 interaction,
the human homolog of Bre2,
ASH2L, has been shown to interact
with the human homolog of Sdc1,
DPY-30 (23). Similar to Bre2 and
Sdc1, the regions important for howASH2L and DPY-30 inter-
act have not been established. In addition, no protein-protein
interaction domains that mediate the interaction between
ASH2L andDPY-30 have been identified. AlthoughASH2L has
a conserved SPRY domain, it is distinct from Bre2 because it
also contains a PHD zinc finger (Figs. 3A and 5A). DPY-30 and
Sdc1 appear to be more similar because they both contain a
Dpy-30 domain, with each being 41 amino acids in size as
reported by Pfam with a 35.7% identity and 73.8% similarity
(Figs. 1A and 5A and supplemental Fig. S1A) (44). GST fusion
binding assays were performed to determine direct interaction
betweenASH2L andDPY-30.GST-DPY-30,GST, and glutathi-
one-agarose beads were incubated with extracts expressing
full-length His6-ASH2L (Fig. 5B, lanes 1–3). Our results show
that ASH2L andDPY-30 can directly interact without the addi-
tion of other MLL- and SET1-associated protein factors. Simi-
lar to Sdc1, deletion of the highly conserved PXXP (Dpy-30
77–80)motif within the Dpy-30 domain of DPY-30 disrupted
binding of ASH2L (Fig. 5B, lane 4). Because the two highly
conserved leucine residues Leu-134 and Leu-135 of the Dpy-30
domain of Sdc1 are needed for interactingwithBre2,wewanted
to determine if the same conserved leucine residues Leu-65 and
Leu-66 found within the Dpy-30 domain of DPY-30 are needed
for interacting with ASH2L. Similar to the Sdc1 leucine muta-
tions, a DPY-30 mutant (DPY-30 L65E,L66E) was unable to
interact with ASH2L (Fig. 5B, lane 8). These results show the
first functional importance of the conserved PXXP motif and
leucine residues in Sdc1 and DPY-30.
FIGURE 3. The C terminus of Bre2 is required for interaction with Sdc1 in vitro. A, schematic representation
of Bre2 and Bre2 mutants used. The positions of the SPRY domain and SDI domain are indicated. B, GST fusion
binding assays were performed to determine the region within Bre2 responsible for binding Sdc1. Purified
full-length GST-Sdc1 was used to pull down bacterially expressed His6-Bre2 or His6-Bre2 mutants (shown in
panels 1–10) from whole cell extracts. GST and glutathione-agarose beads (Agarose) were used as controls for
nonspecific binding. Input and bound fractions of His6-Bre2 were detected by immunoblotting using anti-His
monoclonal antibody. Immunoblots were stained with Coomassie Blue to indicate the amount of GST and
GST-Sdc1 proteins used.
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To determine if the PHD zinc finger was mediating interac-
tion with the Dpy-30 domain of DPY-30, the N terminus of
ASH2L, which contains a PHD zinc finger, was deleted (Ash2l
156–534) and tested for binding to DPY-30. The PHD zinc
finger deletionmutant could still bind toDPY-30 (Fig. 5B, panel
9), suggesting that the PHD zinc finger has other functions in
theMLL and SETH3K4methyltransferase complexes. Because
theC terminus of Bre2 containing amino acids 475–500 and the
last 26 amino acids of ASH2L are 25.9% identical and are 46.2%
similar, we wanted to determine if the SDI domain in Bre2 was
functionally conserved in ASH2L (supplemental Fig. S1B) (44).
Consistent with our previous results with Bre2, binding of
ASH2Lwith full-length DPY-30 was abolished only when the C
terminus of ASH2L (Ash2L 303–508 and Ash2L 1–508) was
missing (Fig. 5B, panels 10 and 11). These results suggest that
the C terminus of ASH2L likely represents the SDI domain that
we defined in the C terminus of Bre2. Altogether, our study
defines, for the first time, the domains of interaction between
the yeast and human Bre2/ASH2L and Sdc1/DPY-30 subunits.
Furthermore, we define the SDI domain as a novel protein-
protein interaction domain that interacts with the Dpy-30
domain and show that this interaction is functionally conserved
in yeast and humans.
The Binding of Bre2 and Sdc1 in Yeast Requires the SDI-
Dpy30 Domain Interaction—It has previously been reported
that Bre2 and Sdc1 will co-immunoprecipitate from yeast
whole cell extracts (18, 19). There-
fore, we wanted to determine if the
interaction between Bre2 and Sdc1
that occurs in vivo was also medi-
ated by the SDI and Dpy-30 domain
interaction that occurs in vitro.
To determine this, we generated
yeast expression constructs con-
taining FLAG-Sdc1, FLAG-Sdc1
PXXP deletion mutant (FLAG-
Sdc1 146–149), HA-Bre2, or HA-
Bre2 truncation mutant (HA-Bre2
1–404) lacking the SDI domain. All
constructs were expressed from a
CEN plasmid containing a constitu-
tive ADH1 promoter (ADH1p) with
either a LEU2- or URA3-selectable
marker.
To determine if the Dpy-30
domain was responsible for mediat-
ing Sdc1 and Bre2 interactions in
vivo, vector (LEU2), FLAG-Sdc1, or
FLAG-Sdc1 PXXP deletion mutant
(FLAG-Sdc1 146–149) was coex-
pressed with full-length HA-Bre2
or vector (URA3) in a bre2sdc1
double deletion strain. Whole cell
yeast extracts were generated, and
co-IP analysis was preformed from
the bre2sdc1 strain expressing
these constructs. As expected, full-
length HA-Bre2 was able to be co-
immunoprecipitated with FLAG-Sdc1 (Fig. 6A, lane 5). This
co-IP was specific for an Sdc1 and Bre2 interaction because
nonspecific interactions were not detected in lanes expressing
only vectors, HA-Bre2, FLAG-Sdc1, or FLAG-Sdc1 146–149
(Fig. 6A, lanes 1–4, top panel). However, an Sdc1 mutant lack-
ing its PXXPmotif (FLAG-Sdc1146–149) was unable to asso-
ciate with HA-Bre2 in vivo, although equivalent amounts of
full-length Sdc1 and Sdc1 PXXP deletion mutant were immu-
noprecipitated (Fig. 6A, compare lanes 5 and 6, top two panels).
These results are consistent with and support our in vitro GST
fusion binding assays (Fig. 1). The inability of the Sdc1 PXXP
deletion mutant (FLAG-Sdc1 146–149) to co-immunopre-
cipitate Bre2 was not due to varying expression levels of Sdc1,
Sdc1 146–149mutant, or Bre2 because nearly equivalent lev-
els were detected (Fig. 6A, lanes 2–6, bottom two panels).
To determine if the SDI domain was also needed for in vivo
interaction between Bre2 and Sdc1, vector (LEU2) or FLAG-
Sdc1 was coexpressed with vector (URA3), full-length HA-
Bre2, or HA-Bre2 C-terminal truncation mutant (HA-Bre2
1–404) lacking the SDI domain in a bre2sdc1 double dele-
tion strain. Similar to Fig. 6A, co-immunoprecipitation analysis
determined that full-length Sdc1 and Bre2 interact, whereas
FLAG-Sdc1 was unable to co-immunoprecipitate HA-Bre2
1–404 lacking the SDI domain although equal amounts of Sdc1
was immunoprecipitated (Fig. 6B, compare lanes 5 and 6, top
two panel). In addition, the co-IP was specific for an Sdc1 and
FIGURE 4. The SDI domain of Bre2 is sufficient for interaction with Sdc1 in vitro. A, schematic representation of
Bre2 and Bre2 mutants used. Domains are indicated as in Fig. 3. B, GST fusion binding assays were performed to
determine regions necessary for interaction with Sdc1. Purified full-length GST-Sdc1 was used to pull down bacte-
rially expressed His6-Bre2 or His6-Bre2 mutants from whole cell extracts. C, GST fusion binding assays were per-
formed to determine the Bre2 region sufficient for interacting with Sdc1. Purified full-length GST-Bre2 or GST-Bre2
truncation mutants were used to pull down bacterially expressed His6-Sdc1 from whole cell extracts. D, a GST fusion
binding assay was performed to determine if Bre2 is able to form a homodimer in vitro. Purified full-length GST-Sdc1
or GST-Bre2 was used to pull down bacterially expressed His6-Bre2 from whole cell extracts. Controls for B, C, and D
were similar. GST and glutathione-agarose beads (Agarose) were used as controls for nonspecific binding. Input and
bound fractions were detected by immunoblotting using -His monoclonal antibody. Immunoblots were stained
with Coomassie Blue to indicate the amount of GST and GST fusion proteins used.
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Bre2 interaction because nonspecific interactions were not
detected in lanes expressing vectors, HA-Bre2, FLAG-Sdc1, or
HA-Bre2 1–404 (Fig. 6B, lanes 1–4, top panel). Again, these
results are consistent with and sup-
port our in vitro binding assays
(Figs. 3 and 4). The inability of Sdc1
to co-immunoprecipitate with the
Bre2 mutant (Bre2 1–404) lacking
the SDI domainwas not due to vary-
ing expression levels of Sdc1, Bre2,
or Bre2 1–404 because nearly
equivalent levels were detected (Fig.
6B, lanes 2–6, bottom two panels).
Altogether, our results show that
the SDI-Dpy-30 protein-protein
domain interaction is critical for
Bre2 and Sdc1 interaction to occur
in vitro and in vivo. In addition, our
data would suggest that this interac-
tion is probably important for in
vivo histone H3K4 methylation.
Interaction between the Bre2
SDI and Sdc1 Dpy-30 Domains
Is Required for Global H3K4
Methylation—Although we have
defined how Sdc1 and Bre2 interact,
we wanted to determine if the inter-
action between the SDI and Dpy-30
domainwas physiologically relevant
for global H3K4 methylation. To
determine if the Dpy-30 domain of
Sdc1 was necessary for proper
H3K4 methylation, HA-Sdc1 full-
length (Sdc1 1–175), HA-Sdc1 dele-
tion mutant (Sdc1 51–60) lacking
the asparagine-rich region, HA-Sdc1 C-terminal truncation
mutant (Sdc1 1–120) lacking the entire Dpy-30 domain, HA-
Sdc1 mutants (Sdc1 131–140, Sdc1 156–165, Sdc1 146–
149, and Sdc1 P146A,P149A) with deletions or pointmutations
in the Dpy-30 domain, and a HA-Sdc1 (Sdc1 C47A) point
mutation were generated and expressed in the sdc1 strain.
Immunoblot analysis of whole cell extracts using H3K4mono-,
di-, and trimethyl-specific antibodies were used to determine if
the various Sdc1 constructs could rescue theH3K4methylation
defects in an sdc1 strain. As expected, full-length Sdc1
restored the H3K4 methylation in an sdc1 strain to a level
similar to what is seen in wild-type (WT) cells (Fig. 7, compare
lanes 1 and 3, top three panels). Interestingly, an Sdc1 deletion
mutant (Sdc1 1–120) lacking theDpy-30 domain and the ability
to bind Bre2 in vitro and in vivo was unable to rescue H3K4
methylation and had H3K4 methylation levels similar to an
sdc1 strain (Fig. 7, lanes 2 and 5). In addition, all mutations
within the Dpy-30 domain of Sdc1 (Sdc1 131–140, Sdc1
156–165, Sdc1 146–149, and Sdc1 P146A,P149A) that fail
to interact with Bre2 also fail to rescue H3K4 methylation in
sdc1 cells (Fig. 7, lanes 6, 7, 12, and 13). However, all of the
Sdc1 mutants that were still able to interact with Bre2, such as
the Sdc1 51–60 lacking the asparagine-rich sequence or the
Sdc1 C47A point mutation, were fully capable of rescuing
H3K4 methylation (Fig. 7, lanes 4 and 11). These differences in
H3K4 methylation patterns did not appear to be due to differ-
FIGURE 5. ASH2L and DPY-30 interact through their SDI and Dpy-30 domains. A, schematic representation of
ASH2L and DPY-30 and corresponding mutants used. Positions of annotated domains are depicted. B, GST fusion
binding assays were performed to determine critical regions for ASH2L and DPY-30 interaction. Purified full-length
GST-DPY-30, GST-Dpy-30 77–80, or GST-Dpy-30 L65E,L66E was used to pull down bacterially expressed His6-
ASH2L or His6-Ash2L mutants from whole cell extracts. GST and glutathione-agarose beads (Agarose) were used as
controls for nonspecific binding. Input and bound fractions of His6-ASH2L and His6-Ash2L mutants were detected
by immunoblotting using anti-His monoclonal antibody. Immunoblots were stained with Coomassie Blue to indi-
cate the amount of GST, GST-DPY-30, GST-Dpy-30 77–80, and GST-Dpy-30 L65E,L66E proteins used.
FIGURE 6. The SDI and Dpy-30 domains are required for Bre2 and Sdc1
protein-protein interaction in vivo. A and B, whole cell extracts expressing
vector or the indicated Sdc1 or Bre2 constructs in bre2sdc1 strains were
immunoprecipitated (IP) with M2 -FLAG resin. Detection of FLAG-Sdc1,
FLAG-Sdc1 mutants, HA-Bre2, or HA-Bre2 mutants were determined by
immunoblotting with -FLAG or -HA antibodies.
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ences in histone H3 loading or expression of Sdc1 or Sdc1
mutants because nearly equivalent levels of histone H3 and
Sdc1 expression were detected (Fig. 7, lanes 1–13, bottom two
panels).
To investigate if the SDI domain of Bre2 was necessary for
proper H3K4 methylation, full-length HA-Bre2 (Bre2 1–505),
HA-Bre2mutant (Bre2 1–404) lacking the C terminus contain-
ing the SDI domain, and HA-Bre2 deletion mutant (Bre2
410–421, Bre2 445–474, and Bre2 474–500) constructs
were generated and expressed in a bre2 strain. Immunoblot
analysis of whole cell extracts using H3K4 mono-, di-, and tri-
methyl-specific antibodies were used to determine if the vari-
ous Bre2 constructs could rescue theH3K4methylation defects
in a bre2 strain. As expected, full-length Bre2 could rescue
H3K4 methylation in a bre2 strain similar to wild-type levels
(Fig. 7, compare lanes 14 and 16). Interestingly, all Bre2
mutants (Bre 1–404, Bre2 445–474, and Bre2 474–500)
that are compromised in their ability to bind Sdc1 were unable
to rescue theH3K4methylation defects of a bre2 strain (Fig. 7,
compare lanes 15, 17, 19, and 20). In contrast, a Bre2 deletion
mutant (Bre2 410–421) retaining the SDI domain and ability
to bind Sdc1 was able to rescue H3K4 methylation (Fig. 7, lane
18). The differences in ability to rescue H3K4 methylation lev-
els in strains expressing Bre2 or the Bre2 mutants were not due
to varying levels of protein expression or histone H3 levels
because-HA andH3 immunoblots detected nearly equivalent
amounts of Bre2, Bre2 mutants, and histone H3 protein (Fig. 7,
lanes 14–20, bottom two panels).
Interaction between the Bre2 SDI and Sdc1 Dpy-30 Domains
Is Required for Association with Set1 and Proper H3K4
Methylation—Prior work has suggested that the Bre2 and Sdc1
heteromer must be formed prior to incorporation into the Set1
complex, because deletion of either Bre2 or Sdc1 will prevent
the other protein from interacting with the Set1 complex (18,
32). Furthermore, our data show
that disrupting the binding between
the SDI domain of Bre2 and Dpy-30
domain of Sdc1 in vivo leads to
defects in global levels of H3K4
methylation similar to what is seen
in bre2 and sdc1 deletion strains
(Fig. 7). To determine if mutations
in the Dpy-30 domain of Sdc1
and/or deletion of the SDI domain
of Bre2 prevented interaction with
Set1, BRE2 and SDC1 were both
deleted in a yeast strain where Set1
was N-terminally Myc3-tagged at
its endogenous locus (Myc3-Set1).
Vector (LEU2), HA-Bre2, HA-Bre2
475–500, FLAG-Sdc1, and FLAG-
Sdc1 L134I,L135I constructs were
coexpressed with vector (URA3),
HA-Bre2, or FLAG-Sdc1 in the
Myc3-SET1, bre2, sdc1 strain. As
expected, immunoprecipitated Set1
could co-immunoprecipitate full-
length HA-Bre2 and FLAG-Sdc1
when cells were co-expressing wild-
type Bre2 and Sdc1 (Fig. 8A, lane 6).
The co-IP of Bre2 and Sdc1 by Set1
is specific because we do not detect
nonspecific interactions in lanes ex-
pressing only vectors (Fig. 8A, lane 1).
FIGURE 7. The SDI and Dpy-30 domains are required for proper levels of
global histone H3K4 methylation. Yeast whole cell extracts generated
from wild-type (WT), sdc1, and bre2 strains expressing vector, Sdc1, or
Bre2 constructs were immunoblotted with histone H3K4 mono-, di-, and
trimethyl-specific antibodies. Histone H3 and HA immunoblots were used
for a loading control or detection of Sdc1 and Bre2 protein levels,
respectively.
FIGURE 8. The SDI-Dpy-30 domain interaction is required for the Bre2 and Sdc1 heteromeric complex to
associate with Set1. A, co-immunoprecipitation analysis from Myc3-SET1, bre2sdc1 strains expressing vec-
tor or the indicated Sdc1 or Bre2 constructs. Detection of Myc3-Set1, FLAG-Sdc1, FLAG-Sdc1 mutants, HA-Bre2,
or HA-Bre2 mutants was determined by immunoblotting with -Myc, -FLAG, or -HA antibodies.
B, whole cell extracts generated from Myc3-SET1, bre2, and sdc1 strains expressing vector or the indicated
Sdc1 or Bre2 constructs were immunoblotted with histone H3K4 mono-, di-, and trimethyl-specific antibodies.
Histone H3 immunoblots were used for a loading control.
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In contrast, Set1 could not co-immunoprecipitate HA-Bre2 or
HA-Bre2 475–500 in the absence of Sdc1 or co-immunopre-
cipitate FLAG-Sdc1 or FLAG-Sdc1 L134I,L135I in the absence
of Bre2 (Fig. 8A, lanes 2, 3, 4, and 5). Furthermore, Set1 failed to
co-immunoprecipitate HA-Bre2 475–500 or FLAG-Sdc1
L134I,L135I in the presence of wild-type Sdc1 or Bre2, respec-
tively (Fig. 8A, lanes 7 and 8). The inability of HA-Bre2, FLAG-
Sdc1, HA-Bre2 475–500, or FLAG-Sdc1 L134I,L135I to co-
immunoprecipitate with Set1 was not due to significant change
in protein expression levels because nearly equivalent levels
were detected (Fig. 8A, lanes 2–8, bottom two panels). In addi-
tion, nearly equivalent levels of Set1 were immunoprecipitated
in all samples (Fig. 8A, lanes 1–8, top panel). In agreement with
the co-immunoprecipitation data, global H3K4mono-, di-, and
trimethylation are only restored when Bre2 and Sdc1 can inter-
act and associate with Set1 (Fig. 8B, lane 6). In contrast, when
Bre2 and Sdc1 cannot interact and thus cannot associate with
Set1, global H3K4methylation remains defective (Fig. 8B, lanes
2–5, 7, and 8). Taken together, our results show that the SDI-
Dpy-30 interaction is not only critical for mediating a Bre2-
Sdc1 heteromeric complex but also necessary for Bre2 and Sdc1
to associate with Set1. These results also help explain why dis-
rupting the SDI-Dpy-30 interaction leads to defects in global
H3K4mono-, di-, and trimethylation. Further investigationwill
be needed to determine if the SDI and Dpy-30 domains are
directly or indirectly associating with Set1 or if other regions
within Bre2 and Sdc1 are responsible for direct or indirect con-
tact with Set1.
The Bre2 SDI and Sdc1 Dpy-30
Domains Are Required for Gene-
specific Methylation and Proper
Gene Expression—To verify that
defects in global H3K4 methylation
observed by Bre2 and Sdc1 mutants
lacking the C-terminal SDI domain
or the Dpy-30 domain, respectively,
also occur on genes, ChIP analysis
was performed on the GMP synthe-
tase, GUA1, and malate dehy-
drogenase, MDH2, open reading
frames using H3K4 di- and tri-
methyl-specific antibodies. ChIP
inputs and histone H3 antibodies
were used as controls (Fig. 9, A and
B, bottom two panels). Chromatin
immunoprecipitation eluates were
analyzed by standard PCR using
primers designed to analyze the 5-
and 3-ends of GUA1 and MDH2
(supplemental Table S4). We chose
to examine H3K4 di- and trimethyl-
ation levels at GUA1 and MDH2
because in a recently published
microarray analysis, GUA1 and
MDH2 were shown to be putative
targets of the E3 ubiquitin ligase
Not4 (47). In addition, it has
recently been shown that Set1,
Not4, and Jhd2 canmodulateH3K4methylation levels atGUA1
(35). Similar to global histonemethylation levels, a loss ofH3K4
trimethylation and a decrease in dimethylation at the 5- and
3-ends ofGUA1 andMDH2were detected in bre2 and sdc1
strains (Fig. 9,A andB, lanes 3, 4, 9, and 10). However,H3K4 tri-
and dimethylation was restored to wild-type levels when full-
lengthBRE2 and SDC1were ectopically expressed (Fig. 9,A and
B, lanes 5, 6, 11, and 12). Importantly, the Bre2 and Sdc1
mutants that are defective in binding to each other, Bre2 1–404
lacking the SDI domain or Sdc1 146–149 lacking the PXXP
motif within the Dpy-30 domain, had gene-specific H3K4 di-
and trimethylation defects similar to what is observed in bre2
and sdc1 strain (Fig. 9, A and B, lanes 7, 8, 13, and 14).
Set1-mediated H3K4 methylation is important for proper
gene expression (3–6, 8, 35, 48–50). However, until now, it has
not been demonstrated if Bre2 or Sdc1, two Set1-associated
factors required for proper H3K4 methylation, are also needed
for appropriate levels of expression at constitutively active
genes. Because our chromatin immunoprecipitation analysis
determined that a Bre2 and Sdc1 interaction is critical formod-
ulatingH3K4 di- and trimethylation levels atGUA1 andMDH2
open reading frames, we wanted to determine if GUA1 and
MDH2 expression levels were also being modulated. Using
quantitative real-time PCR analysis, we examined gene expres-
sion ofGUA1 andMDH2.We determined that defects inH3K4
histonemethylation that occur in bre2 and sdc1 strains coin-
cided with an about 2-fold decrease in GUA1 expression rela-
tive to wild-type cells (Fig. 10,A and B, and supplemental Table
FIGURE 9. The SDI and Dpy-30 domains are required for proper gene-specific H3K4 methylation. A and B,
ChIP analysis from the indicated strains was performed using antibodies specific to H3K4 di- and trimethylation
and histone H3. ChIP eluates were PCR-amplified using primer sets directed to the 5- and 3-ends of the open
reading frames of GUA1 and MDH2 and analyzed by agarose gel electrophoresis and ethidium bromide stain-
ing. Input and histone H3 were used as loading controls. The depicted ChIP analysis is a representation of three
biological repeats. WT, wild type.
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S5). This decrease in GUA1 expression was similar to what we
have observed for set1 and not4 strains (35). Furthermore,
GUA1 gene expression levels in bre2 and sdc1 expressing
full-length Bre2 and Sdc1, respectively, were rescued at levels
similar to those of wild type (Fig. 10,A and B, and supplemental
Table S5). More importantly, Bre2 and Sdc1 mutants (Bre2
1–404, and Sdc1146–149) that were defective in binding and
H3K4 methylation showed a decrease inGUA1 expression lev-
els (Fig. 10, A and B, and supplemental Table S5).
To confirm that these changes in GUA1 transcript levels
were not specific only to theGUA1 locus, theMDH2 locus was
also analyzed. Similar to GUA1, MDH2 transcript levels were
decreased about 3-fold in bre2 and sdc1 strains when com-
pared with wild-type cells (Fig. 10, C and D, and supplemental
Table S5). Furthermore,MDH2 gene expression levels in bre2
and sdc1 expressing full-length Bre2 and Sdc1, respectively,
were rescued to nearly wild-type levels (Fig. 10, C and D, and
supplemental Table S5). More importantly, Bre2 and Sdc1
mutants (Bre2 1–404 and Sdc1 146–149) that were defective
in binding and H3K4 methylation also showed a defect in
MDH2 expression levels (Fig. 10, A and B, and supplemental
Table S5). Altogether, our results show that when interactions
between Bre2 and Sdc1 are disrupted, Bre2 and Sdc1 no longer
associate with each other or Set1; consequently, this leads to
defects in global and gene-specific histone H3K4 methylation
and decreases in gene expression.
DISCUSSION
In this study, we determined for the first time how two Set1-
associated subunits, Bre2 and Sdc1, form a heteromeric com-
plex. We show that the Dpy-30 domain of Sdc1 is critical for
mediating interactions with Bre2.We identified a new protein-
protein interaction domain located at the C terminus of Bre2,
which we have named the SDI domain because it is needed to
interactwith theDpy-30 domain of Sdc1.More importantly, we
show that the SDI-Dpy-30 domain interaction is required for
formation of the heteromeric Bre2 and Sdc1 complex and asso-
ciation with Set1. Without this interaction, histone H3K4
methylation and gene expression is disrupted. Finally, we deter-
mine that the human homologs of Bre2 and Sdc1, ASH2L and
DPY-30, respectively, also associate in a similar manner involv-
ing the C terminus of ASH2L and the Dpy-30 domain of DPY-
30. Our findings would suggest that the SDI-Dpy-30 domain
interaction is a conserved interaction for yeast Set1 and human
MLL and SET1-like complexes. The ASH2L and DPY-30 inter-
action is also likely to impact histone H3K4 methylation and
gene expression in humans and other organisms.
In this study, we determined that the Dpy-30 domains of
Sdc1 and humanDPY-30 are required for interacting with Bre2
and ASH2L, respectively. Because all mutations within the
Dpy-30 domain of Sdc1 disrupted interaction with Bre2, it is
likely that the overall structure of the Dpy-30 domain is impor-
tant for interacting with the C terminus of Bre2. Interestingly,
during preparation of this manuscript, the x-ray crystal struc-
ture of the Dpy-30 domain of human DPY-30 was solved (45).
The structure indicates that the human DPY-30 domain can
form a four-helix bundle. Based on the human crystal structure
and structure prediction analysis of yeast Sdc1, it appears that
deletions of the PXXP motif or mutations that change the pro-
lines to alanines are within a loop region connecting two -he-
lices (45, 51). Therefore, it is likely that this loop is important for
the overall structure or position of the two -helices. In addi-
tion, thismight explainwhy Sdc1 deletionmutationswithin the
predicted helices on either side of the PXXP loop would disrupt
binding to Bre2 (Fig. 1B). From the crystal structure, it was also
predicted that two highly conserved leucine residues, Leu-65
and Leu-66, form a putative binding pocket for interactionwith
ASH2L (45). Our data support this idea and show that muta-
tions of the conserved leucines in Sdc1 and DPY-30 disrupt
binding to Bre2 and ASH2L, respectively (Figs. 1B and 5B).
It has been predicted that Dpy-30 dimerization is important
for Sdc1 and Bre2 association with Set1 (1). This idea is based
on bacterial two-hybrid analysis of Sdc1 indicating that the
Dpy-30 domain can dimerize and on the predicted stoichiom-
etry of the individual Set1-associated proteins within the Set1
complex (18, 32). In addition, the recently solved x-ray crystal
structure of the Dpy-30 domain of human DPY-30 also forms a
dimer (45). Although we also show that Sdc1 could form disul-
fide-mediated dimers from bacterially expressed Sdc1, we were
unable to determine if there is any physiological relevance for
Sdc1 dimerization in yeast. For example, we were unable to
detect disulfide-mediated dimerization of Sdc1 from yeast
(data not shown), and a mutation of Sdc1 (Sdc1 C47A) that
abolished dimerization in vitro had no effect on H3K4 methyl-
ation in vivo or binding to Bre2 (Figs. 2, C and D, and 7). More
work will be needed to determine if the disulfide-dependent or
independent dimerization of Sdc1 is physiologically relevant or
an artifact of bacterial expression and/or crystallization condi-
tions. It is also possible that the Sdc1 or DPY-30 dimerization
observed in vitro occurs because a physiologically relevant
binding partner, such as the SDI domain of Bre2 or ASH2L, is
not present. Therefore, future studies with the co-crystal of the
SDI domain of Bre2 or ASH2L with Sdc1 or DPY-30, respec-
tively, would be useful in clarifying the importance of Sdc1 and
DPY-30 dimerization.
FIGURE 10. The SDI and Dpy-30 domains are required for appropriate
levels of gene expression. A–D, expression of GUA1 or MDH2 was deter-
mined in the indicated strains by quantitative real-time PCR analysis. All
expression analysis was relative to wild-type (WT) cells using actin (ACT1) as
an internal control to normalize expression levels. Data in A–D were analyzed
from four biological repeats with three technical repeats each.
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A surprising result from ourmutational analysis and binding
studies indicated that the C termini of Bre2 and ASH2L are
important for interacting with Sdc1 and DPY-30, respectively.
This result was quite interesting because the only domain com-
mon to both Bre2 and ASH2L that was annotated as a protein-
protein interaction domain is the SPRY domain. The function
of the SPRY domain is currently unknown, but it is likely to be
important for interacting with either Set1, Set1-associated sub-
units within the yeast and humanMLL and SET1 complexes, or
other transcription factors (15, 52). In this study, we have iden-
tified a new protein-protein interaction domain within Bre2
and ASH2L that we named the SDI domain. By homology
searching, the SDI domain of Bre2 and ASH2L showed no sig-
nificant matches to any other known domain. However, sec-
ondary structure prediction of the SDI domain of Bre2 and
ASH2L suggests that the C terminus forms an-helix structure
(44). Interestingly, a domain that shares similarity to the
Dyp-30 domain is the RIIa domain. Structural analysis has indi-
cated that the Dpy-30 and RIIa domains can both form four-
helix bundles and can dimerize. RIIa domains are commonly
found within the regulatory subunit of cyclic AMP-dependent
protein kinase A and are required for dimerization (41, 43).
Recently, the structure of the RIIa domain and its binding part-
ner A kinase-anchoring protein has been solved, and it was
determined that an A kinase-anchoring protein -helix was
bound to the RIIa domain (41, 43). Intriguingly, when we com-
pared the C terminus of Bre2 and mouse A kinase-anchoring
protein -helix that binds the RIIa domain, there was a 22.1%
identity (44). Currently, it is unclear if the A kinase-anchoring
protein -helix is functionally similar to the SDI domain or
structurally similar butwith specificity toward the RIIa domain.
Because of the functional conservation of the SDI predicted
-helical domain from yeast to humans, the SDI domain or
domains of structural similarity may be important for interac-
tion with other Dpy-30 or RIIa domains containing partners.
Based on our data, the crystal structure of the human Dpy-30
domain, and the conserved amino acids within the SDI and
Dpy-30 domains, it is likely that the SDI-Dpy-30 interaction is
mediated by the conserved hydrophobic and/or charged amino
acids (supplemental Fig. S1). However, additional biochemical
and structural studies will be needed to determine the precise
mode of interaction.
In this study, we also show that an interaction between the
SDI domain of Bre2 and the Dpy-30 domain of Sdc1 is func-
tionally important for Bre2 and Sdc1 to form a heteromeric
complex and associationwith Set1 so that proper histonemeth-
ylation and gene expression can occur. However, more work
will be needed to establish the regions within Bre2 and Sdc1
required for association with Set1 or other Set1 complex mem-
bers. Based on our work and recent data suggesting that Bre2,
Sdc1, and ASH2L bind to the SET domain of yeast Set1 or
human MLL1, it is likely that the Bre2 and Sdc1 heteromeric
complex permits interaction with the SET domain of Set1,
allowing for full methyltransferase activity (18, 32, 53–55).
Because we also showed that humanASH2L andDPY-30 inter-
act in a similar manner, we would expect this interaction could
enhance the in vitro catalytic activity of the human MLL- and
SET1-like complex or be required for in vivo trimethylation.
Although it is still unclear if an SDI-Dpy-30 domain interaction
is required, RNA interference knockdown of either human
ASH2L orC. elegansDPY-30 can lead to defects inH3K4meth-
ylation (20, 30, 56). In addition, it has recently been shown that
recombinant ASH2L and DPY-30 heteromeric dimer and
RbBP5 by itself can stimulate the catalytic activity of recombi-
nant MLL1 by directly binding to the SET domain (53–55).
However, the addition of both heteromeric dimers, ASH2L-
DPY-30 and Wdr5-RbBP5, to recombinant MLL results in a
further enhancement of catalytic activity (53–55). It has been
proposed that the heteromeric dimers help stabilize the SET
domains of MLL and SET1-like methyltransferases, so the SET
domain is in the right conformation for full methyltransferase
activity (53). Future studies will be required to determine if the
SDI-Dpy-30 domain interaction is required for stabilizing the
SET domain conformation and for H3K4 methylation in other
organisms.
Although bre2 and sdc1 strains have been shown to have
histone methylation defects, the basic observation that disrup-
tion of histone methylation in these strains coincides with
defects in gene expression within euchromatin has not been
reported. In this study, we show that loss of BRE2 or SDC1 or
disruption of their SDI-Dpy-30 domain interaction results in
expression defects at constitutively active genes. In addition,
the decrease in gene expression observed at two loci strongly
coincides with H3K4methylation defects and is also consistent
with microarray analysis of a set1 deletion strain showing a
general 2-fold defect in global gene expression (8, 48, 50).
Because RNA interference knockdown of ASH2L in mamma-
lian cells results in histone methylation and gene expression
defects, we would expect that disruption of the SDI-Dpy-30
interaction would also result in gene expression defects in
human and other organisms (20, 30). Recently, ASH2L has also
been found overexpressed in cancer cells and is thought to
function as an oncoprotein (57). Although themolecularmech-
anism by which ASH2L mediates oncogenesis is unknown, it
could be due to a consequence of either too little or toomuch of
an association with DPY-30, resulting in reduced or overactive
MLL or SET1 methyltransferase activity and consequently
leading to aberrant gene expression. Therefore, our study and
others that determine the interaction and function of yeast and
human Set1-associated proteins are important and will proba-
bly impact human health and diseases and provide insight into
novel therapeutic targets.
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